Drakeley Christopher J, Jawara Musa, Targett Geoffrey A T, Walraven Gijs, Obisike Uche, Coleman Rosalind, Pinder Margaret, Sutherland Colin J
Joint Malaria Programme, Moshi, Tanzania.
Trop Med Int Health. 2004 Jan;9(1):53-61. doi: 10.1046/j.1365-3156.2003.01169.x.
Combination therapy using existing anti-malarials together with artesunate (AS) has been advocated as a method to slow the spread of drug resistance. We assessed the effect on Plasmodium falciparum transmissibility of the addition of AS to chloroquine (CQ) in an area of The Gambia where resistance to CQ is increasing.
Gambian children with acute uncomplicated P. falciparum malaria were treated with either CQ monotherapy (n=120) or the combination of CQ plus three doses of AS (CQ/AS; n=352). Post-treatment sexual-stage parasitaemia was assessed during a 4-week follow-up period. Experimental infections of Anopheles gambiae s.s. mosquitoes were performed with blood from patients who were carrying gametocytes 7 days after starting treatment (n=69).
The addition of AS significantly reduced post-treatment prevalence and mean density of gametocytes in the first 14 days (day 7: 43.7% vs. 12.4%, 62.4/microl vs. 6.2/microl; day 14: 32.9% vs. 3.7%; 21.9/microl vs. 5.2/microl; CQ vs. CQ/AS), although by day 28 the benefits of the combination were substantially less marked (40.5% vs. 21.8%; 23.0/microl vs. 63.1/microl; CQ vs. CQ/AS). The duration of gametocyte carriage over the study period was significantly lower in the CQ/AS group (5.2 days vs. 1.5 days; CQ vs. CQ/AS). The estimated infectious proportion of children at day 7 was also lower in the combination group (19.2% vs. 3.4%; CQ vs. CQ/AS), as were the proportion of mosquitoes infected and mean oocyst density (11.5% vs. 0.9%; 0.3 vs. 0.01; CQ vs. CQ/AS). Treatment failure was associated with threefold and twofold higher gametocyte carriage rates during follow-up in CQ and CQ/AS groups, respectively (P<0.001 in both cases), and 26-fold and 2.3-fold higher intensity of infection at day 7 among CQ- and CQ/AS-treated children, respectively (P=0.002 and 0.30, respectively).
The benefits of adding AS to CQ monotherapy in lowering gametocyte prevalence and density were transient, suggesting that the addition of AS delayed, but did not prevent, the emergence of gametocytes. This is consistent with our finding that treatment failure, and thus the presence of CQ-resistant parasites, was significantly associated with a higher gametocyte carriage rate in both treatment groups. At day 7, CQ monotherapy significantly favoured transmission of resistant infections, which showed an 11-fold greater intensity of transmission compared with infections that were successfully treated. In contrast, the combination of CQ/AS did not significantly favour resistant infections at day 7. We conclude that significant transmission-reduction is achieved by the combination but is not maintained because of the recrudescence of CQ-resistant parasites.
提倡使用现有的抗疟药物与青蒿琥酯(AS)联合治疗,作为减缓耐药性传播的一种方法。在冈比亚一个氯喹(CQ)耐药性不断增加的地区,我们评估了在CQ中添加AS对恶性疟原虫传播性的影响。
患有急性非复杂性恶性疟原虫疟疾的冈比亚儿童,分别接受CQ单药治疗(n = 120)或CQ联合三剂AS的治疗(CQ/AS;n = 352)。在4周的随访期内评估治疗后性阶段寄生虫血症。用开始治疗7天后携带配子体的患者的血液对冈比亚按蚊进行实验感染(n = 69)。
添加AS显著降低了治疗后前14天配子体的患病率和平均密度(第7天:43.7%对12.4%,62.4/微升对6.2/微升;第14天:32.9%对3.7%;21.9/微升对5.2/微升;CQ对CQ/AS),尽管到第28天,联合治疗的益处明显减弱(40.5%对21.8%;23.0/微升对63.1/微升;CQ对CQ/AS)。在研究期间,CQ/AS组配子体携带的持续时间显著缩短(5.2天对1.5天;CQ对CQ/AS)。联合治疗组第7天儿童的估计感染比例也较低(19.2%对3.4%;CQ对CQ/AS),感染蚊子的比例和平均卵囊密度也是如此(11.5%对0.9%;0.3对0.01;CQ对CQ/AS)。治疗失败与CQ组和CQ/AS组随访期间配子体携带率分别高出三倍和两倍相关(两种情况P均<0.001),且CQ治疗组和CQ/AS治疗组儿童第7天的感染强度分别高出26倍和2.3倍(分别为P = 0.002和0.30)。
在CQ单药治疗中添加AS在降低配子体患病率和密度方面的益处是短暂的,这表明添加AS延迟但未阻止配子体的出现。这与我们的发现一致,即治疗失败以及因此存在的CQ耐药寄生虫与两个治疗组中较高的配子体携带率显著相关。在第7天,CQ单药治疗显著有利于耐药感染的传播,与成功治疗的感染相比,其传播强度高11倍。相比之下,CQ/AS联合治疗在第7天对耐药感染没有显著促进作用。我们得出结论,联合治疗可实现显著的传播减少,但由于CQ耐药寄生虫的复发而无法维持。